These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33780111)

  • 1. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
    Pitance V; Désage S; Lienhart A; Meunier S; Chamouard V
    Haemophilia; 2021 May; 27(3):e368-e375. PubMed ID: 33780111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe.
    Blatný J; Nielsen EM; Reitzel SB; McMillan AC; Danø A; Bystrická L; Kragh N; Klamroth R
    Haemophilia; 2023 Jul; 29(4):963-974. PubMed ID: 37243934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
    Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
    Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
    Hakimi Z; Santagostino E; Postma MJ; Nazir J
    Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
    Lorenzoni V; Triulzi I; Turchetti G
    BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
    Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
    BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIII Fc for the treatment of haemophilia A.
    Hermans C; Mancuso ME; Nolan B; Pasi KJ
    Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data.
    Farahbakhshian S; Fan Q; Schultz BG; Princic N; Park J; Bullano M
    J Med Econ; 2023; 26(1):1278-1286. PubMed ID: 37787429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.